Comprehensive Clinical Guide: Intermittent Hemodialysis (IHD) Prescription & Initiation

Intermittent Hemodialysis (IHD) remains the gold standard for extracorporeal blood purification in patients with end-stage renal disease (ESRD) and acute kidney injury (AKI) requiring rapid solute clearance. As a high-efficiency modality, IHD utilizes the principles of diffusion and convection to restore homeostasis in patients whose native kidneys can no longer perform filtration, excretion, and endocrine functions.

1. Introduction & Overview

Intermittent Hemodialysis is a procedure where blood is pumped out of the body through a vascular access device, passed through a semi-permeable membrane (the dialyzer), and returned to the patient. Unlike Continuous Renal Replacement Therapy (CRRT), which runs 24/7 at lower blood flow rates, IHD is characterized by high blood flow rates (300–500 mL/min) and high dialysate flow rates, typically delivered over a 3- to 4-hour session, 3 to 4 times per week.

The primary goal of IHD is to manage fluid overload, correct electrolyte imbalances (hyperkalemia), remove nitrogenous waste products (uremia), and correct acid-base disturbances (metabolic acidosis).

2. Technical Specifications & Mechanisms

The efficacy of IHD is governed by the principles of mass transfer. The dialyzer acts as the artificial kidney, consisting of thousands of hollow fibers.

Core Mechanisms

• Diffusion: Movement of solutes (urea, creatinine, potassium) from an area of high concentration (blood) to an area of low concentration (dialysate) across a semi-permeable membrane.
• Convection (Ultrafiltration): The movement of water and dissolved solutes across the membrane driven by a pressure gradient (transmembrane pressure).
• Adsorption: The binding of specific middle-weight molecules to the surface of the dialyzer membrane.

Standard Prescription Parameters

3. Clinical Indications & Usage

Indications for Urgent Initiation (The "AEIOU" Mnemonic)

• A - Acidosis: Refractory metabolic acidosis (pH < 7.1).
• E - Electrolyte Imbalance: Severe hyperkalemia (K+ > 6.5 mEq/L) resistant to medical management.
• I - Intoxications: Removal of dialyzable toxins (e.g., ethylene glycol, methanol, lithium).
• O - Overload: Refractory pulmonary edema or volume overload.
• U - Uremia: Uremic complications (pericarditis, encephalopathy, bleeding diathesis).

Chronic Indications

• End-Stage Renal Disease (ESRD) with a GFR < 10–15 mL/min/1.73m².
• Failure of peritoneal dialysis or kidney transplantation.

4. Patient Pre-Op Preparation & Vascular Access

Preparation is critical to minimize intradialytic complications.

Vascular Access Hierarchy

1. Arteriovenous Fistula (AVF): Gold standard; surgical connection of artery to vein (preferred for longevity).
2. Arteriovenous Graft (AVG): Synthetic tube connection; used when native vessels are inadequate.
3. Tunneled Central Venous Catheter (CVC): Bridge access; high risk of infection and thrombosis.

Pre-Initiation Checklist

• Weight Assessment: Determine "dry weight" (estimated weight without excess fluid).
• Hemodynamic Baseline: Blood pressure, heart rate, and oxygen saturation.
• Medication Reconciliation: Hold antihypertensives prior to treatment to avoid intradialytic hypotension.
• Laboratory Review: Check pre-dialysis potassium, bicarbonate, and BUN levels.

5. The Procedure: Initiation Protocol

1. Cannulation/Connection: Under aseptic technique, access the vascular site.
2. Priming: Ensure the extracorporeal circuit is primed with sterile saline to prevent air embolism.
3. Anticoagulation: Administer heparin or citrate to prevent clotting in the circuit, unless the patient is at high risk for hemorrhage.
4. Initiation: Gradually increase blood flow (Qb) to the target rate over 5–10 minutes to allow for hemodynamic adjustment.
5. Monitoring: Continuous monitoring of transmembrane pressure (TMP), venous pressure, and arterial pressure.

6. Post-Op Recovery & Management

Post-dialysis care is focused on stabilizing the patient and evaluating the success of the clearance.

• Hemodynamic Stabilization: Monitor for hypotension or arrhythmias post-treatment.
• Access Care: Apply pressure dressings to cannulation sites; observe for hematoma or bleeding.
• Weight Check: Compare post-dialysis weight to target dry weight.
• Rebound Monitoring: Monitor for "disequilibrium syndrome" (headache, nausea, confusion) caused by rapid shifts in osmolarity.

7. Risks, Side Effects, and Contraindications

Common Complications

• Intradialytic Hypotension (IDH): The most common complication, often due to aggressive ultrafiltration.
• Muscle Cramps: Usually related to rapid volume removal or electrolyte shifts.
• Dialysis Disequilibrium Syndrome: Neurological symptoms due to rapid lowering of blood urea nitrogen (BUN).
• Vascular Access Infection: Particularly with catheters.

Contraindications

• Severe hemodynamic instability (refractory shock).
• Lack of viable vascular access.
• Active, uncontrollable hemorrhage (relative contraindication depending on anticoagulation strategy).

8. Alternative Treatments

When IHD is not feasible or appropriate, clinicians may pivot to:
* CRRT (Continuous Renal Replacement Therapy): Ideal for ICU patients with hemodynamic instability; provides slow, continuous fluid removal.
* Peritoneal Dialysis (PD): Uses the peritoneal membrane; performed at home by the patient.
* SLED (Sustained Low-Efficiency Dialysis): A hybrid of IHD and CRRT; 6–12 hour sessions at lower blood flow rates.

9. Frequently Asked Questions (FAQ)

1. How is "dry weight" determined?

Dry weight is the weight at which the patient is normotensive and asymptomatic. It is determined through clinical trial and error, monitoring for signs of fluid overload (edema, hypertension) vs. dehydration (hypotension, cramping).

2. Can I eat during dialysis?

Eating is generally discouraged during the first hour of treatment, as blood is diverted to the gastrointestinal tract, which may exacerbate intradialytic hypotension.

3. Why does my blood pressure drop during treatment?

The drop is usually caused by the rapid removal of intravascular fluid, which the body cannot compensate for quickly enough via vasoconstriction.

4. What is the difference between IHD and CRRT?

IHD is faster and intermittent (3–4 hours), whereas CRRT is slow and continuous (24 hours). CRRT is better tolerated by hemodynamically unstable patients.

5. Are there specific medications that should be avoided before dialysis?

Antihypertensives are often held because dialysis itself lowers blood pressure, and combining the two can cause severe hypotension.

6. How often should a fistula be checked?

Fistulas should be checked daily for a "thrill" (vibration) and "bruit" (whooshing sound). Absence of these indicates potential stenosis or thrombosis.

7. What is Dialysis Disequilibrium Syndrome?

It is a neurological complication caused by the rapid removal of urea, leading to cerebral edema. It is prevented by starting the first few dialysis sessions with shorter durations and lower blood flow rates.

8. Is dialysis painful?

The cannulation of the vascular access can cause discomfort, but the dialysis procedure itself should be painless.

9. What causes muscle cramps during treatment?

Cramps are typically caused by fluid volume depletion, rapid sodium shifts, or electrolyte imbalances (hypocalcemia/hypomagnesemia).

10. Can dialysis cure kidney failure?

No. Dialysis is a life-sustaining treatment, not a cure. It replaces kidney function until a transplant is performed or in cases of AKI, until the kidneys recover.

10. Conclusion

Intermittent Hemodialysis is a sophisticated, life-saving intervention that requires meticulous prescription, monitoring, and patient education. By understanding the kinetics of solute clearance and the physiological impact of fluid removal, healthcare providers can significantly improve outcomes for patients suffering from acute and chronic kidney failure. Success in IHD is defined not just by the clearance of toxins, but by the maintenance of hemodynamic stability and the preservation of long-term vascular access.